Stromal antigen targeting by a humanised monoclonal antibody: An early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer

Onkologie

Volumn 26, Issue 1, 2003, Pages 44-48

  Hofheinz, Ralf Dieter ^a,e   Al Batran, S E ^b   Hartmann, F ^c   Hartung, G ^a   Jager D ^b   Renner, C ^c   Tanswell, P ^d   Kunz, U ^d   Amelsberg, A ^d   Kuthan, H ^d   Stehle, G ^d  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b KRANKENHAUS NORDWEST   (Germany)

^c Medizinische Klinik und Poliklinik   (Germany)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^e I Medizinische Klinik   (Germany)

Author keywords

Colorectal cancer; Fibroblast activation protein; Human anti human antibody; Monoclonal antibody; Pharmacokinetics

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; SIBROTUZUMAB; UNCLASSIFIED DRUG;

ADULT; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BRONCHOSPASM; CANCER GROWTH; CANCER REGRESSION; CHILL; CHOLANGITIS; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; FLUSHING; HUMAN; INFUSION; LIVER INJURY; MALE; METASTASIS; MULTICENTER STUDY; NAUSEA; PAIN; PHASE 2 CLINICAL TRIAL; PROTEIN TARGETING; RIGOR; SEPSIS; STROMA CELL; THROMBOCYTOPENIA;

AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PALLIATIVE CARE; SERINE ENDOPEPTIDASES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0037219532     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000069863     Document Type: Article

References (16)

1. Welt S, Ritter G: Antibodies in the therapy of colon cancer. Semin Oncol 1999;26:683-690.
2. Foon KA, Yannelli J, Bhattacharya-Chatterjee M: Colorectal cancer as a model for immunotherapy. Clin Cancer Res 1999;5:225-236.
3. Riechmann L, Clark M, Waldmann H, Winter G: Reshaping human antibodies for therapy. Nature 1988;332:323-327.
4. Green MC, Murray JL, Hortobagyi GN: Monoclo-nal antibody therapy for solid tumors. Cancer Treat Rev 2000;26:269-286.
5. Mathew S, Scanlan MJ, Mohan Raj BK, Murty VS, Garin-Chesa P, Old LJ, Rettig WJ, Chaganti RSK: The gene for fibroblast activation protein (FAP), a putative cell surface-bound serine protease expressed in cancer stroma and wound healing maps to chromosome band 2q23. Genomics 1995;25:335-337.
6. Niedermeyer J, Scanlan MJ, Garin-Chesa P, Daiber C, Fiebig HH, Old LJ, Rettig WJ, Schnapp A: Mouse fibroblast activation protein: Molecular cloning, alternative splicing and expression in the reactive stroma of epithelial cancers. Int J Cancer 1997;71:383-389.
7. Garin-Chesa P, Old LJ, Rettig WJ: Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody-target in human epithelial cancers. Proc Natl Acad Sci U S A 1990;87:7235-7239.
8. Kaminski MS, Zasadny KR, Francis IR, Milik AW, Ross CW, Moon SD, Crawford SM, Burgess JM, Petry NA, Butchko GM, Glenn SD, Wahl RL: Radioimmunotherapy of B-cell lymphoma with [131I] anti-B1 (anti-CD20) antibody. New Engl J Med 1993;329:459-465.
9. Jurcic JG, Caron PC, Nikula TK, Papadopoulos EB, Finn RD, Gansow OA, Miller WH, Geerlings MW, Warrell RP, Larson S, Scheinberg DA: Radio-labeled anti-CD33 monoclonal antibody M195 for myeloid leukemias. Cancer Res (suppl) 1995;55: 5908s-5910s.
10. Waldmann TA, Goldman CK, Bongiovanni KF, Sharrow SO, Davey MP, Cease KB, Greenberg J, Longo D: Therapy of patients with human T-cell lymphotropic virus I-induced adult T-cell leukemia with anti-Tac, a monoclonal antibody to the receptor for interleukin-2. Blood 1988;78:1805-1816.
11. Welt S, Divgi CR, Scott AM, Garin-Chesa P, Finn RD, Graham M, Carswell EA, Cohen A, Larson MS, Old LJ, Rettig WJ: Antibody targeting in metastatic colon cancer: A phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts. J Clin Oncol 1994;12:1193-1203.
12. Scott AM, Wiseman G, Welt S, Lee F, Hopkins W, Mitchell P, Adjei A, Divgi C, Larson S, Hoffman E, Tanswell P, Bette P, Amelsberg A, Rettig W, Old L: A phase I dose-escalation study of BIBH 1 in patients with advanced or metastatic fibroblast activation protein positive cancer. Proc ASCO 2001;20: 258a.
13. Reff ME, Heard C: A review of modifications to recombinant antibodies: Attempt to increase efficacy in oncology applications. CRC Crit Rev Oncol Hematol 2001;40:25-35.
14. Boeckman AJ, Beal SL, Sheiner LB: NONMEM User's Guides. NONMEM Project Group, University of California at San Francisco, San Francisco, 1998.
15. Tanswell P, Garin-Chesa P, Rettig WJ, Welt S, Divgi CR, Casper ES, Finn RD, Larson SM, Old LJ, Scott AM: Population pharmacokinetics of anti-fibroblast activation protein monoclonal antibody F19 in cancer patients. Br J Clin Pharmacol 2001;51:177-180.
16. Hellström I, Beaumier PL, Hellström KE: Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas. Proc Natl Acad Sci U S A 1986;83:7059-7063.